Sanath Savithri Nandeesha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sanath Savithri Nandeesha has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Adnan Rafiq Karajgi
Kempegowda Institute of Medical Sciences, India
1 shared publication Alousious Kasagga
Pathology, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA
1 shared publication- Bhanumathi Vasudeva
Bangalore Medical College and Research Institute, India
1 shared publication Chnoor Hawrami
Pediatric Surgery, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA
1 shared publication- Dipin R
Kempegowda Institute of Medical Sciences, India
1 shared publication Erica Ricci
Anesthesiology, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA
1 shared publication
Latest Publications
- Open Access
- 23 September 2025
- Published by MDPI AG in Preprints.org
Precursor B-Cell Lymphoblastic Leukemia Presenting as Thyrotoxic Goiter: A Case Report and Narrative Review of Evidence
We report a rare case of precursor B-cell lymphoblastic leukemia presenting as thyrotoxic goiter, highlighting the diagnostic challenges posed by the overlapping symptomatology of acute leukemia and hyperthyroidism. Such presentations may arise from direct leukemic thyroid infiltration or hematologic complications of antithyroid medications. Our patient, a 32-year-old woman with untreated hyperthyroidism, developed classic thyrotoxic features with hematological abnormalities that ultimately led to a leukemia diagnosis. This case underscores the importance of heightened vigilance when evaluating thyroid abnormalities in patients with hematologic manifestations.
- 23 September 2025
- Published by MDPI AG in Preprints.org
Open AccessPrecursor B-Cell Lymphoblastic Leukemia Presenting as Thyrotoxic Goiter: A Case Report and Narrative Review of Evidence
We report a rare case of precursor B-cell lymphoblastic leukemia presenting as thyrotoxic goiter, highlighting the diagnostic challenges posed by the overlapping symptomatology of acute leukemia and hyperthyroidism. Such presentations may arise from direct leukemic thyroid infiltration or hematologic complications of antithyroid medications. Our patient, a 32-year-old woman with untreated hyperthyroidism, developed classic thyrotoxic features with hematological abnormalities that ultimately led to a leukemia diagnosis. This case underscores the importance of heightened vigilance when evaluating thyroid abnormalities in patients with hematologic manifestations.
- Open Access
- 17 September 2025
- Published by MDPI AG in Preprints.org
Tirzepatide and Gut Microbiome: A Narrative Review of Current Evidence and Future Implications
Tirzepatide has recently been approved for use with type 2 diabetes and obesity due to its effectiveness with both and being the first dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Increasing focus has shifted toward tirzepatide’s possible relationships with the gut microbiome, which plays an important role in metabolic, bile acid, and inflammation regulation, in addition to its many established benefits in glucose control and weight loss. Gut microbial composition changes are known to lead to obesity, insulin resistance, and related comorbidities, which is why this area is so important. Tirzepatide has been shown to increase the absent flora diversity of the gut in addition to the increased growth of beneficial Akkermansia and Bacteroides, and the alteration of bile acid metabolism toward microbial antagonists of the farnesoid X receptor. Lubricated insulin resistance and systemic inflammation, coupled with the imbalance of gut flora resulting from a diet high in fats, have been linked to these changes. Preliminary studies support the idea that tirzepatide’s dual mechanism has a more profound influence over the microbial ecology and metabolic pathways than the effects of other GLP-1 receptor agonists and DPP-4 inhibitors. Overall, the safety data regarding tirzepatide appear to be in line with other therapies based on incretins, with gastrointestinal side effects being the most common adverse event. Its effects on metabolism and the microbiome, however, are broader than glucose and weight management. Early data suggest potential benefits in NAFLD, inflammatory bowel disease, cardiovascular dysfunction, and even some neurodegenerative diseases. Tirzepatide embodies a promising advance in the intersection of incretin biology and gut microbiome regulation for precision medicine in metabolic disease. The focus on the microbiome in future studies will be important for substantiating and elucidating the mechanisms of these observations, enhancing patient stratification for precision medicine approaches.
- 17 September 2025
- Published by MDPI AG in Preprints.org
Open AccessTirzepatide and Gut Microbiome: A Narrative Review of Current Evidence and Future Implications
Tirzepatide has recently been approved for use with type 2 diabetes and obesity due to its effectiveness with both and being the first dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Increasing focus has shifted toward tirzepatide’s possible relationships with the gut microbiome, which plays an important role in metabolic, bile acid, and inflammation regulation, in addition to its many established benefits in glucose control and weight loss. Gut microbial composition changes are known to lead to obesity, insulin resistance, and related comorbidities, which is why this area is so important. Tirzepatide has been shown to increase the absent flora diversity of the gut in addition to the increased growth of beneficial Akkermansia and Bacteroides, and the alteration of bile acid metabolism toward microbial antagonists of the farnesoid X receptor. Lubricated insulin resistance and systemic inflammation, coupled with the imbalance of gut flora resulting from a diet high in fats, have been linked to these changes. Preliminary studies support the idea that tirzepatide’s dual mechanism has a more profound influence over the microbial ecology and metabolic pathways than the effects of other GLP-1 receptor agonists and DPP-4 inhibitors. Overall, the safety data regarding tirzepatide appear to be in line with other therapies based on incretins, with gastrointestinal side effects being the most common adverse event. Its effects on metabolism and the microbiome, however, are broader than glucose and weight management. Early data suggest potential benefits in NAFLD, inflammatory bowel disease, cardiovascular dysfunction, and even some neurodegenerative diseases. Tirzepatide embodies a promising advance in the intersection of incretin biology and gut microbiome regulation for precision medicine in metabolic disease. The focus on the microbiome in future studies will be important for substantiating and elucidating the mechanisms of these observations, enhancing patient stratification for precision medicine approaches.
- 10 August 2024
- Published by Elsevier in Current Problems in Cardiology
- Vol. 49 (11) , 102789
Empowering treatment decisions: ChatGPT in severe coronary artery disease
- 10 August 2024
- Published by Elsevier in Current Problems in Cardiology
- Vol. 49 (11) , 102789
Empowering treatment decisions: ChatGPT in severe coronary artery disease
- Open Access
- 27 March 2024
- Published by Springer Nature in Cureus
- Vol. 16 (3) , e57066
Treatment Efficacy of Plasmapheresis Versus Intravenous Immunoglobulin in Guillain-Barré Syndrome Management: A Systematic Review
Guillain-Barré syndrome (GBS) is a rare and debilitating autoimmune disorder that affects the peripheral nervous system. Although the exact etiology of GBS is still unknown, it is thought to be triggered by a preceding gastrointestinal infection in most of the cases. Clinical manifestations include limb weakness, areflexia, and sensory loss that can further progress to neuromuscular paralysis affecting the respiratory, facial, and bulbar functions. Both plasmapheresis (PE) and intravenous immunoglobulin (IVIG) have shown effectiveness in the treatment of GBS, but it is still unclear which treatment approach is superior in terms of therapeutic efficacy. This systematic review acts per Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 2020 guidelines. For appropriate studies and research, we searched PubMed, PubMed Central (PMC), Medical Literature Analysis and Retrieval System Online (MEDLINE), Science Direct, and Google Scholar. Screening of articles was performed based on relevance and inclusion and exclusion criteria. To check for bias, we used relevant quality appraisal tools. Initially, we found 2454 articles. After removing duplicates and irrelevant papers, we finalized 31 studies based on titles, abstracts, and reading entire articles. We excluded 14 studies because of poor quality; the remaining 17 papers were included in this review. IVIG is equally efficacious as PE in improving primary outcomes and secondary outcomes. IVIG showed a slight advantage over PE in reducing the need for mechanical ventilation (MV) and hospital stay duration. However, in children, PE demonstrated a slight edge in improving secondary outcomes. PE was associated with a slightly higher risk of adverse events and post-treatment worsening symptoms compared to IVIG. IVIG is considered more user-friendly with a significantly lower patient discontinuation rate than PE. IVIG treatment was found to be significantly more expensive than PE.
- 27 March 2024
- Published by Springer Nature in Cureus
- Vol. 16 (3) , e57066
Open AccessTreatment Efficacy of Plasmapheresis Versus Intravenous Immunoglobulin in Guillain-Barré Syndrome Management: A Systematic Review
Guillain-Barré syndrome (GBS) is a rare and debilitating autoimmune disorder that affects the peripheral nervous system. Although the exact etiology of GBS is still unknown, it is thought to be triggered by a preceding gastrointestinal infection in most of the cases. Clinical manifestations include limb weakness, areflexia, and sensory loss that can further progress to neuromuscular paralysis affecting the respiratory, facial, and bulbar functions. Both plasmapheresis (PE) and intravenous immunoglobulin (IVIG) have shown effectiveness in the treatment of GBS, but it is still unclear which treatment approach is superior in terms of therapeutic efficacy. This systematic review acts per Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 2020 guidelines. For appropriate studies and research, we searched PubMed, PubMed Central (PMC), Medical Literature Analysis and Retrieval System Online (MEDLINE), Science Direct, and Google Scholar. Screening of articles was performed based on relevance and inclusion and exclusion criteria. To check for bias, we used relevant quality appraisal tools. Initially, we found 2454 articles. After removing duplicates and irrelevant papers, we finalized 31 studies based on titles, abstracts, and reading entire articles. We excluded 14 studies because of poor quality; the remaining 17 papers were included in this review. IVIG is equally efficacious as PE in improving primary outcomes and secondary outcomes. IVIG showed a slight advantage over PE in reducing the need for mechanical ventilation (MV) and hospital stay duration. However, in children, PE demonstrated a slight edge in improving secondary outcomes. PE was associated with a slightly higher risk of adverse events and post-treatment worsening symptoms compared to IVIG. IVIG is considered more user-friendly with a significantly lower patient discontinuation rate than PE. IVIG treatment was found to be significantly more expensive than PE.